Αρχική World News The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable Hepatocellular...

The Investigational PD1 Antibody, Tislelizumab, Shows Promise in Patients With Unresectable Hepatocellular Carcinoma

A novel anti-PD1 agent, tislelizumab, is under development for the treatment of patients with solid tumours and has demonstrated clinical benefit in unresectable hepatocellular carcinoma (HCC), according to findings from a phase II study presented at the ESMO World Congress on Gastrointestinal Cancer 2021, which was held from 30 June to 3 July 2021.

Ghassan K. Abou-Alfa of the Department of Medicine, Memorial Sloan Kettering Cancer Center in New York, USA explained that tislelizumab is an investigational monoclonal antibody with high affinity and binding specificity for PD1. It was specifically designed to minimise binding of the FcyR on macrophages to help abrogate antibody-dependent phagocytosis, which figures in T-cell clearance and is a potential mechanism of resistance to anti-PD1 therapy.

Supporting evidence for tislelizumab was provided in two early phase studies (NCT02407990, CTR20160872) where it was administered as monotherapy in patients with advanced solid tumours, including HCC. Both studies demonstrated preliminary anti-tumour activity with tislelizumab, which was generally well-tolerated.

The global phase II study (NCT03419897) presented at this Congress evaluated single-agent tislelizumab administered at 200 mg i.v. every 3 weeks in 249 patients with unresectable HCC. The patients’ median age was 62 years. HCC was classified as Child-Pugh A and Barcelona Clinic Liver Cancer (BCLC) stage B or C; at study entry, 225 (90%) patients had BCLC stage C and 200 (80%) had extrahepatic spread. Regarding prior systemic treatment, 111 (45%) patients had received ≥2 prior systemic therapies including sorafenib in 233 (94%) patients.

The overall response rate by independent review committee (IRC; ORRIRC) per RECIST v1.1 served as the primary endpoint and the secondary endpoints were progression-free survival by IRC (PFSIRC), ORR per investigator (ORRINV), duration of response (DoR), overall survival (OS), and the safety/tolerability profile of tislelizumab.

Response evaluations of both the independent review committee and investigator were in accord

In the overall patient population, the confirmed ORRIRC was 12.4% (95% confidence interval [CI] 8.6-17.2), which included 2 complete responses (CR) and 29 partial responses (PR). DoRIRC was not reached (NR) with median follow-up of 9.1 months.

Evaluation of the secondary endpoints provided an ORRINV of 14.1% (95% CI 10-19.0), which included 1 CR and 34 PRs.

Median OS was 12.4 months (95% CI 10.8-NR) and the one-year OS rate was 51.9% (95% CI 44-59). Median PFS was 2.7 months (95% CI 1.5-2.8).

In addition, the investigators found that the response and survival estimates were unaffected by the number of prior lines of therapy.  Patients having 1 line of previous therapy demonstrated an ORRIRC of 13.0% (95% CI 7.9-19.8) and those with ≥2 prior lines had an ORRIRC of 11.7% (95% CI 6.4-19.2). In patients with 1 prior treatment line, the median OS was 13.0 months (95% CI 10.5-NR) and median PFS was 2.6 months (95% CI 1.4, 2.8); in patients with ≥2 prior lines, the median OS and PFS were 11.8 months (95% CI 10.6-NR) and 2.7 months (95% CI 1.4-2.8), respectively.

The most common treatment-related adverse events (TRAEs) were increased AST, which occurred in 30 (12%) patients, and ALT in 2 (9%) patients. The only grade 3–4 TRAE occurring in ≥2% of patients was increased AST, which was reported in 6 (2%) patients.

Fatal AEs occurred in two patients consisting of infectious pneumonia and hepatic encephalopathy in one patient each; neither death was attributed to treatment according to the investigators.

Conclusions

Based on these findings, the investigators remarked that tislelizumab demonstrated durable responses and was well tolerated in patients with unresectable HCC that had been received previous systemic treatment.

They noted that these patients have a continued high unmet medical need.

They also announced that there is an ongoing large, global, randomised phase III study (NCT03412773) comparing tislelizumab with sorafenib as a reference standard in first-line treatment for adult patients with unresectable HCC.

Prof. Chris J. Verslype of the University Hospital in Leuven, Belgium, who discussed the study findings, said that it was a phase II study, however with no details on translational studies. Tislelizumab is an active and safe investigational PD1 antibody in second- and third-line setting (without prior anti-PD1/PD-L1 therapy) that is comparable to other anti-PD1 agents. In terms of further developments, Prof. Verslype commented that ongoing phase III study in first-line setting of tislelizumab versus sorafenib is unlikely to yield clinically relevant results.   

Funding from BeiGene, Ltd. was disclosed.

Reference

O–1. Ducreux M, Abou-Alfa G, Ren Z, et al. Results from a Global Phase 2 Study of Tislelizumab, an Investigational PD-1 Antibody, in Patients With Unresectable Hepatocellular Carcinoma. ESMO World Congress on Gastrointestinal Cancer 2021 (30 June – 3 July).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling of Breast Implants

In 2013, Kristen Carbone, of Providence, Rhode Island, had a preventative mastectomy to help protect herself against breast cancer after her mother died of...

FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

On 30 November 2021, the US Food and Drug Administration (FDA) approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen,...

Thanks For Making This GivingTuesday Our Best One Yet!

We set ambitious goals for GivingTuesday, but they were driven by a time of great need. With your help, we hoped to provide food and...

Over 600 people in England set to benefit from innovative lung cancer treatment

<img width="620" height="348" src="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg" class="attachment-featuredImage size-featuredImage" alt="Lung cancer cell" loading="lazy" srcset="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg 620w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-300x168.jpg 300w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-220x123.jpg 220w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-150x84.jpg 150w" sizes="(max-width: 620px) 100vw, 620px" data-attachment-id="18781" data-permalink="https://news.cancerresearchuk.org/2020/09/11/targeted-drug-for-lung-cancer-approved-for-nhs-use-in-england/lung_cell_cropped-hero/"...

Touching a nerve: How neuroscience could advance our understanding of cancer

KTSDESIGN/SCIENCE PHOTO LIBRARY When supporters donate to our work, their combined generosity might lead to a new discovery that inches us closer to, for example,...

Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP

An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of...